Conditions: Neoplasms
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 60
Healthy volunteers: no

Brief summary:
A phase II trial to assess the impact of afatinib (BIBW 2992) on the heart (QTcF) and the effectiveness of afatinib (BIBW 2992) in treating certain cancers. Cancers studied will include glioblastoma and cancers which have spread to the brain (metastases).

Detailed description:

Arms:
arm 1: BIBW 2992 high dose, once daily, continuous, monotherapy

Interventions: intervention 1: BIBW 2992
Intervention descriptions: intervention 1: patients to receive continuous oral daily dosing of BIBW 2992

Protocol document: